TY - JOUR
T1 - HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.
AU - Theys, Kristof
AU - Vercauteren, Jurgen
AU - Snoeck, Joke
AU - Zazzi, Maurizio
AU - Camacho, Ricardo Jorge
AU - Torti, Carlo
AU - Schülter, Eugen
AU - Clotet, Bonaventura
AU - Sonnerborg, A
AU - De Luca, A.
AU - Grossman, Zehava
AU - Struck, Daniel
AU - Vandamme, Anne-mieke
AU - Abecasis, Ana
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.
AB - Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.
U2 - 10.1128/AAC.01668-12
DO - 10.1128/AAC.01668-12
M3 - Article
C2 - 23183438
VL - 57
SP - 1053
EP - 1056
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 2
ER -
